Almac Sciences Adds Biologics Testing to its Analytical Solutions Suite

Publication
Article
In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter 10-07-2020
Volume 15
Issue 10

With a recent expansion, Almac will now have the ability to include enhanced analytical method development and bioanalytical testing.

Almac Sciences, a member of the Almac Group, is undergoing expansion to add biologics testing to its suite of analytical solutions.

The expansion will include current good manufacturing practice (CGMP) lot release and stability testing, fit-for-purpose analytical method development, phase-appropriate method validation, and raw material testing for microbial and mammalian expression systems.

“Biologics have gained huge traction in the last decade and are poised for stronger growth in the coming years with potential to significantly impact patient lives,” said Dr. John Robson, vice-president, Analytical Operations, Almac Sciences, in a Sept. 24, 2020 company press release. “The launch of this service offering furthermore demonstrates Almac’s commitment to offering a best-in-class service to our global client base and in advancing human health. We are confident the addition of biologics testing solutions will continue to strengthen our competitive position in the marketplace.”

Source: Almac

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Drug Digest: Focusing on Solid Dosage Trends and Demand
Behind the Headlines, episode 7
Related Content